AGIO: Q3 revenue topped $55M as AQVESME demand grew and mitapivat advanced toward a 2027 FDA decision

What happened

Agios reported third-quarter revenue of $55 million, more than four times the prior-year quarter, as U.S. demand for AQVESME expanded. The company had $907.0 million in cash, moved mitapivat’s sickle cell PDUFA date—a target date for an FDA decision—to February 1, 2027, and set a 2028 non-GAAP profitability goal.

Confirmed

Global impact / market context

Revenue growth alongside a substantial cash balance may give Agios resources to support AQVESME sales and advance mitapivat while awaiting the FDA decision. Reaching the 2028 profitability goal will depend on whether revenue growth can outpace ongoing costs; the supplied figures do not establish that outcome.

Analyst inference

The update presents two different signals: rapidly higher quarterly revenue and a later target date for an FDA decision on mitapivat. The cash figure and 2028 profitability goal provide context for funding and execution, but the supplied information does not show whether the goal is on track.

Analyst inference

What to watch

1. Track whether AQVESME demand continues to expand in the U.S. and whether that growth translates into higher revenue in subsequent reported quarters. Analyst inference
2. Watch for updates to mitapivat’s sickle cell PDUFA date of February 1, 2027, the target date for an FDA decision. Confirmed
3. Compare future revenue and costs with the 2028 non-GAAP profitability goal; non-GAAP profit excludes certain items under the company’s chosen measure. Analyst inference

Evidence

• Original source link unavailable